Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th
March 30, 2022 09:00 ET
|
Cassava Sciences, Inc.
– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates – – Stakeholders Are Invited to Submit Questions via Email – – Fireside Chat Will Be Open to The Public via Webcast – AUSTIN,...
Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates
February 28, 2022 16:03 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for...
FDA Denies Citizen Petitions Filed on Behalf of Short Selling Clients
February 10, 2022 16:07 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that the U.S. Food and...
Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease
December 23, 2021 09:00 ET
|
Cassava Sciences, Inc.
New website (www.Rethink-ALZ.com) is intended to increase visibility and information for potential study participants.Rethink-ALZ.com connects patients with nearest participating clinical site.Phase 3...
Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Publication
December 21, 2021 09:30 ET
|
Cassava Sciences, Inc.
Editor-in-Chief States: “After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the Western Blot Data or Other Figures of This...
Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease
November 18, 2021 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, announced today it has initiated a second Phase 3 study of simufilam, the Company’s...
Cassava Sciences Reports Third Quarter 2021 Financial Results
November 10, 2021 09:00 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for...
Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences’ Lead Drug Candidate
November 04, 2021 09:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) has been informed by the Journal of Neuroscience that there is no evidence of data manipulation in an article...
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease
October 06, 2021 08:30 ET
|
Cassava Sciences, Inc.
First Phase 3 Study is Initiated to Evaluate Safety and Efficacy of Simufilam Over 52 Weeks in 750 Patients with Alzheimer’s DiseaseA Second Phase 3 Study, Expected to Begin by Year End, Will Evaluate...
Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer’s Disease
September 22, 2021 08:30 ET
|
Cassava Sciences, Inc.
Cognition Scores Improved 3.2 Points on ADAS-Cog, Baseline to Month 12 (p<0.001) Two Independent Biostatisticians Analyzed Changes in ADAS-Cog Scores, Baseline to Month 12No Behavior Disorders on...